lindas have a posse
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree that $15-20 far too low for NWBO:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169815671
Given NWBO has no competition as well as iron-clad patent protection plus exclusivity as it treats an orphan disease, I would say that time certainly are on the side of management and shareholders. Our only risk involves improper execution which so far has been avoided masterfully.
I am sure Al Capone and Jesse James thought they were playing the long game.
Though you can't run from the law.
The Phase V Short Sellers brought us to OTC. You have not done enough due diligence into this company's long history or the decades-plus-long manipulation of its stock.
Here's the Phase V author bragging about nearly bankrupting NWBO:
Was able to locate the original $NWBO Phase Five note which crashed the stock & led to its Nasdaq delisting in 2015 - link below.
— Jssr (@juliaskripkaser) October 16, 2020
This ultimate fraud is once again flying high on false promises to new shareholders. Only fair that they know what this is🤷♀️ https://t.co/DHPEjYENlm
The trial was a clinicial success:
https://nwbio.com/presentation-about-phase-3-trial-of-dcvax-l-for-glioblastoma/
Sawston plant can scale up to 12K patients per year:
https://nwbio.com/northwest-biotherapeutics-announces-presentations-on-dcvax-l-personalized-vaccines-manufacturing-and-scale-up-and-dcvax-l-clinical-program/
Final commercial manufacturing license submitted:
https://nwbio.com/northwest-biotherapeutics-announces-filing-of-application-for-license-for-commercial-manufacturing-at-sawston-uk-facility/
MHRA endorsed PIII trial design by applying it to Pediatric Investigation Plan:
https://nwbio.com/northwest-biotherapeutics-announces-approval-of-pediatric-investigation-plan-pip-by-mhra-pip-approval-is-a-pre-requisite-for-application-for-approval-of-a-new-medicine-for-adult-patients/
Regulatory approval moving forward while shareholders are behind our world-class management:
https://nwbio.com/northwest-biotherapeutics-announces-positive-votes-at-annual-meeting-reviews-2022-progress-and-looks-forward-to-strong-2023/
So given all of this success the more apt question would be why haven't management been rewarded further by Mr Market?
No other biotech firm has an autologous treatment for all solid tumors so your comparative analysis, which has no acceptable peers, isn't valid.
Management are well on their way having completed hundreds of thousands of pages for regulatory approval application. I personally believe they're engaged in FDA RTOR. Though even if they're not I don't really care.
DCVax will be worth hundreds of billions. I trust our world-class management will deliver results as they have had nothing but success.
Conversations between the FDA and a company seeking drug approval are not public. We are not going to see NWBO explain the day to day especially not while matters are before regulators. They do not want to make public statements which could be interpreted as seeking to influence the approval process. If you are not aware of this then you haven't done basic due diligence.
The FDA has much discretion throughout the drug approval process so it behooves shareholders to trust that our management team, scientific advisory board, and top tier-legal representation are doing what's required to deliver DCVax to GBM patients in the United States. Linda Powers helped author the EU's Patent Law as well as NAFTA. We have excellent firms on retainer. If you don't have confidence in the process well sorry management can't please everyone. They're focused on the regulators.
Remember that NWBO are up 116% over 5 years!
XBI up only 0.2% over 5 years.
F up 27% over 5 years.
GM up 0.27% over 5 years
IBM down 5% over 5 years.
DAL down 21% over 5 years.
WBA down 46% over 5 years.
NWBO, with no revenue, performing better than entire biotech sector as well as companies with exponentially higher market caps!
How?
The market potential!
Shorts don't have evidence.
Not for longs who will be rich.
There was no double dosing.
Great buying opportunity whenever these drop.
We need an infographic of the early trials with DCVax. I believe they're prostate, pancreatic, and ovarian but I could be missing others.
Loose lips sink ships
I agree Gary. Globally Keytruda reaches less than 0.2% of all new patients diagnosed with cancer. It's an insidious disease. Our autologous approach will work well for the many heterogeneous types of cancer. We simply need to ensure scalable manufacturing as well as robust patent protection. It seems the company have all of this well under control. So it's only patience for us shareholders.
Billionaire Robert Hefner disagrees:
Our Northwest Biotherapeutics (NWBO) investee “partner” likely has just made one of the biggest breakthroughs in the history of cancer. We know that is a really big statement so why do we at GHK believe that is possible? Because we believe the doors through which major cancer breakthroughs must pass are the human immune system, immunotherapies and personalized vaccines and NWBO has just leaped through those doors with its personalized DCVax vaccine made from your own cells.
You can argue about trial statistics until the cows come home but the bottom line is 1) people living longer 2) quality of life during treatments and 3) the cost of treatments.
During NWBO’s 16-year Phase III trial to treat glioblastoma (GBM), one of the most difficult and lethal of all solid tumor cancers 1) more people lived longer, 2) it is safe with virtually no side effects occurring and 3) NWBO estimates treatments will cost about half as much as Standard of Care chemotherapy and radiation treatments. So for the first time ever, GBM patients can have hope! And can hope like prayer increase the effectiveness and energy of the immune system? We think so.
We are aware we stuck our necks out when we said “possibly one of the biggest breakthroughs in the history of cancer”. So we have listed below our three principle reasons so you can decide for yourself:
After 417 failed GBM trials treating 31,952 patents over decades, DCVax-L is first treatment that gives GBM patients a meaningful chance to live longer, some now living 9 to as many as 19 years and counting.
DCVax was conceived and created not for glioblastoma alone but as a personalized tool of your own immune system to defeat all solid tumor cancers and that’s 90% of all cancers.
Since DCVax’s creation NWBO has amassed an enormous rich databank containing masses of information on patients, treatments, and DCVax’s use against 15 different solid tumor cancers that has not yet been analyzed by artificial intelligence (AI). We believe that in the near future when these vast amounts of data and information are teamed with AI and some of the world’s leading scientists and doctors that future generations of DCVax vaccines and protocols will experience great leaps forward in effectiveness at lower and lower costs for 90% of all cancers.
So to sum up, we believe NWBO with its DCVax immunotherapy personalized vaccines has leaped through the doors and will play a vital role in humanities great drive to defeat cancer once and for all.
Dr. Ashkan is the genius behind this viral vid of him performing brain surgery while his patient was awakened to play the violin…mid-surgery. He told me he champions DCVax-L bc of trial data along with what he’s seen first-hand from his patients. $NWBOhttps://t.co/XFTeSPFtH5
— Wade Kovash (@wkovash) June 6, 2022
Watch one of the world’s preeminent neurosurgeons explain the significance of $NWBO ‘s Phase III trial of DCVax-L. The results are groundbreaking and represent an enormous advancement in one of the most tragic cancers. https://t.co/eQw5tAsivK
— Wade Kovash (@wkovash) June 6, 2022
Not all dendritic vaccines are created equal! Thank you dstock!
NWBO are a prerevenue biotech that developed two versions of an autologous cancer vaccine, two independent manufacturing processes, has global patent protection, as well as delivered nothing but successful trial results.
Let me say that again.
Every DCVax trial has been successful!
They also got JAMA and a top DC law firm to sue basically all of Wall Street on contingency!
Management did all of this for less than the mean cost of developing a single drug which comes out to around 2 Billion USD!
We are so lucky to be shareholders of Northwest Biotherapeutics!
Remember that NWBO are up 116% over 5 years!
XBI up only 0.2% over 5 years.
F up 27% over 5 years.
GM up 0.27% over 5 years
IBM down 5% over 5 years.
DAL down 21% over 5 years.
WBA down 46% over 5 years.
NWBO, with no revenue, performing better than entire biotech sector as well as companies with exponentially higher market caps!
How?
The market potential!
We are not mixing up large batches of diethyltoluamide. Things happen. Adults deal with it.
Novocure sent out a trial success statement with no data to back it up. That could have been the intent of NWBO though they waited until more data was available probably at advice of their regulatory consultants or scientific advisory committee. Either way it doesn't matter at this stage. The Landmark Trial was a resounding success with near universal support in the oncology community. That's what matters.
You do not seem to understand how markets work. When an individual like Hefner takes a position it's wise to listen. As I stated many times he created the natural gas industry. He has had the ears of many world leaders given his wide-ranging expertise. It's not a logical fallacy to notice when the best of us talk. That's called responsible due diligence.
We don't have a trillion-dollar market cap pharmaceutical company because the market penetration for their drugs isn't very large. Keytruda reaches less than 1% of all new global cancer patients diagnosed each year. If we can address all solid tumors at an affordable price while maintaining a durable competitive advantage through unique manufacturing and patent protection then we have an unlimited upside with DCVax.
Said below right before JAMA so will yet again:
It's pretty absurd that longs are accused of abandoning the company if they don't post on social media. When at the same time if they do post a price target or potential timeline they're accused of being part of an illegal pump and dump scheme.
Absurd.
Many of us are enthusiastic retail supporters who believe in the Landmark Trial Results as well as monumental achievements which management have secured.These include Innovative Manufacturing and Global Patent Protection!
We found this undervalued gem during the dark days of Covid when we had time for deep due diligence.
We're not leaving at bottom of the 9th in Game 7. Sorry. MHRA endorsed the trial and the NIH gave a huge thumbs up Linda Liau's SNO Plenary on 11/20. Abstract embargo ends 11/11. Stay tuned.
Billionaire Robert Hefner disagrees:
Our Northwest Biotherapeutics (NWBO) investee “partner” likely has just made one of the biggest breakthroughs in the history of cancer. We know that is a really big statement so why do we at GHK believe that is possible? Because we believe the doors through which major cancer breakthroughs must pass are the human immune system, immunotherapies and personalized vaccines and NWBO has just leaped through those doors with its personalized DCVax vaccine made from your own cells.
You can argue about trial statistics until the cows come home but the bottom line is 1) people living longer 2) quality of life during treatments and 3) the cost of treatments.
During NWBO’s 16-year Phase III trial to treat glioblastoma (GBM), one of the most difficult and lethal of all solid tumor cancers 1) more people lived longer, 2) it is safe with virtually no side effects occurring and 3) NWBO estimates treatments will cost about half as much as Standard of Care chemotherapy and radiation treatments. So for the first time ever, GBM patients can have hope! And can hope like prayer increase the effectiveness and energy of the immune system? We think so.
We are aware we stuck our necks out when we said “possibly one of the biggest breakthroughs in the history of cancer”. So we have listed below our three principle reasons so you can decide for yourself:
After 417 failed GBM trials treating 31,952 patents over decades, DCVax-L is first treatment that gives GBM patients a meaningful chance to live longer, some now living 9 to as many as 19 years and counting.
DCVax was conceived and created not for glioblastoma alone but as a personalized tool of your own immune system to defeat all solid tumor cancers and that’s 90% of all cancers.
Since DCVax’s creation NWBO has amassed an enormous rich databank containing masses of information on patients, treatments, and DCVax’s use against 15 different solid tumor cancers that has not yet been analyzed by artificial intelligence (AI). We believe that in the near future when these vast amounts of data and information are teamed with AI and some of the world’s leading scientists and doctors that future generations of DCVax vaccines and protocols will experience great leaps forward in effectiveness at lower and lower costs for 90% of all cancers.
So to sum up, we believe NWBO with its DCVax immunotherapy personalized vaccines has leaped through the doors and will play a vital role in humanities great drive to defeat cancer once and for all.
Dr. Ashkan is the genius behind this viral vid of him performing brain surgery while his patient was awakened to play the violin…mid-surgery. He told me he champions DCVax-L bc of trial data along with what he’s seen first-hand from his patients. $NWBOhttps://t.co/XFTeSPFtH5
— Wade Kovash (@wkovash) June 6, 2022
Watch one of the world’s preeminent neurosurgeons explain the significance of $NWBO ‘s Phase III trial of DCVax-L. The results are groundbreaking and represent an enormous advancement in one of the most tragic cancers. https://t.co/eQw5tAsivK
— Wade Kovash (@wkovash) June 6, 2022
Keytruda does 20B revenue a year so the global potential immunotherapy market certainly isn't worth 100B. It's many trillions. If DCVax can capture large portion of that market then Linda Powers will be as big if not bigger than Elon Musk in terms of positive impact on humanity.
I really don't care when that happens. I am waiting. If you are too impatient well not everyone gets to live in that house on a hill.
By the way in case people don't know all clinical trials must submit an IND application to the FDA and have it approved before human trials can begin. So the FDA has the legal right to access patient-level data for any approved clinical trial including every single one in the NWBO external control group including Novocure's Optune trial.
So you're saying the National Academy of Sciences are liars when they state regarding Linda Powers:
She was co-lead negotiator for the U.S. on the North American Free Trade Agreement, financial sector agreement, which opened banking, securities, insurance, pension fund and related opportunities in Canada and Mexico.
During the 1980s, Ms. Powers practiced law, specializing in corporate mergers, acquisitions and financings, and certain kinds of intellectual property transactions. While working for the headquarters of the European Union in Brussels, she was responsible for drafting the initial intellectual property rules that now govern know-how licensing in the European Union.
Top DC law firm suing Wall Street on contingency.
Are you defending criminal spoofing?
Bravo, per usual.
Biotech happens to be the most opaque sector of the economy where one can invest.
It sounds like you didn't perform any due diligence.
Management set milestones and they get them done.
Linda Powers made it clear the firm were preparing regulatory filings for drug approval since beginning of 2022.
If you believe she's keeping those 750K pages on the shelves gathering dust while the rest of the 1M document gets assembled then that's rather irrational thinking when the firm are a prime candidate for FDA's Real Time Oncology Review (RTOR).
Being part of such a program enables them to submit sections of the BLA as they are completed. The drug approval process isn't public so we don't know if they're going this route but it would be the path of least resistance.
The company has known trial results since after 2020 data lock while we learned at the 2022 ASM that's one of the key tasks they've been doing along with the UK MIA, validating the Flaskworks technology, furthering patent protection, as well as JAMA, and the groundbreaking spoofing lawsuit.
That's an insane amount of effort for a small company to put forward! The fact that they've delivered on all their milestones means investors should relax while management work on behalf of shareholders and cancer patients.
Everyone please remember that NWBO are up 116% over 5 years!
For context:
XBI up only 0.2% over 5 years.
F up 27% over 5 years.
GM up 0.27% over 5 years
IBM down 5% over 5 years.
DAL down 21% over 5 years.
WBA down 46% over 5 years.
NWBO, with no revenue, performing better than entire biotech sector as well as companies with exponentially higher market caps!
How could that be possible?
The market potential!
NYSE makes a "point in time" determination for an initial listing of $4. Uplisting can be overnight. I don't really think achieving the share price is what would cause us concern. Management want to ensure the price remains high so they want to have adequate news to sell institutional investors. The goal is to end the volatility.
So JAMA, NYAS, UCLA, King's College, NIH, FDA, MHRA, EMA, Health Canada, George HW Bush, Cofer Black, Robert Hefner, and the entire European Union, as she helped draft their patent law, are all victims of this fraud Linda Powers?
Your conclusions seem irrational given the preponderance of the evidence in fact showcase her genius-level intellect, dogged determination, and strategic mastery. I don't think it would be possible for any other CEO to deliver such astounding results. In fact hundreds of other GBM trials failed. For this Linda Powers will be remembered as one of the greatest CEOs of all time.
We have no revenue yet are doing better than Walgreens Boots Alliance which has 13K retail locations, 320K employees, 130B in revenue, and pays a monster dividend.
Clearly NWBO longs are not going to capitulate.
Can you imagine our gains when we actually have approval, revenue, and additional trials in our pipeline?
I think aristocracy could be in our future!